<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82602">
  <stage>Registered</stage>
  <submitdate>13/02/2008</submitdate>
  <approvaldate>15/02/2008</approvaldate>
  <actrnumber>ACTRN12608000088347</actrnumber>
  <trial_identification>
    <studytitle>Post Amputation Phantom Limb Pain Study</studytitle>
    <scientifictitle>Can Pregabalin prevent persistent post amputation pain?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Persistent phantom limb pain post amputation</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>One month course of oral pregabalin commencing with a single preoperative 150md dose of pregabalin, followed by 75mg oral pregabalin BD for 7 days after surgery, then increasing to 75-150mg bd for the following 21 days, a total of 28 days of pregabalin</interventions>
    <comparator>Placebo- calcium carbonate packaged to appear identical to the pregabalin capsule</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>reduction of incidence of phantom pain in treatment group using chi square testing: significant pain versus no significant pain</outcome>
      <timepoint>1 week, one month and six months post amputation surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>improvement in acute postoperative pain which will be measured using the verbal response scale (VRS)</outcome>
      <timepoint>24hrs, 48hrs, 1 week post surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>improvements in analgesic requirements after discharge from acute care hospital</outcome>
      <timepoint>10days, 1 month, 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>improvement in psychological status after lower limb amputation</outcome>
      <timepoint>24hrs, 48hrs, 1 week, 1 month and 6 months post surgery measured using the Hospital and anxiety scale (HADS)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patient able to provide own informed consent.
there is sufficient ime before proposed surgery to allow absorption of loading dose of pregabalin, minimum 2hrs
Patient is suitable for standard general anaesthetic (GA) regimen and able to use patient controlled analgesia (PCA) for postop analgesia</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>N/A</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Current use of gabapentin
Unable to give consent
epilepsy
pregnancy
lactation
significant renal impairment
galactos metabolic disorders</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer</concealment>
    <sequence>permutted blocks with stratified allocation by site</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/03/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2139</postcode>
    <postcode>3000</postcode>
    <postcode>2305</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>John Hunter Hospital-Hunter Integrated Pain Service</primarysponsorname>
    <primarysponsoraddress>Level 2 Exectutive Suite, Royal Newcastle Centre
Lookout Rd
New Lambton NSW 2305</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Inc</fundingname>
      <fundingaddress>235 East 42nd Street
New York NY 10017</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Hunter New England Area Health Service</sponsorname>
      <sponsoraddress>Locked bag 1
Lookout Rd
New Lambton NSW 2305</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to determine whether the use of the drug Pregabalin can reduce or eliminate phantom pain after leg amputations</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>Locked bag 1
New Lambton NSW 2305</ethicaddress>
      <ethicapprovaldate>21/08/2006</ethicapprovaldate>
      <hrec>06/06/28/3.02</hrec>
      <ethicsubmitdate>27/05/2006</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Richard Burstal</name>
      <address>Hunter Integrated Pain Service
Level 2 Executive Suite, Royal Newcastle Centre
Lookout Rd
New Lambton NSW 2305</address>
      <phone>61 2 49223435</phone>
      <fax>61 2 49223574</fax>
      <email>Richard.Burstal@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jeanene Douglas</name>
      <address>Hunter Integrated Pain Service
Level 2 Executive Suite, Royal Newcastle Centre
Lookout Rd
New Lambton NSW 2305</address>
      <phone>61 2 49223435</phone>
      <fax>61 2 49223574</fax>
      <email>Jeanene.Douglas@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jeanene Douglas</name>
      <address>Hunter Integrated Pain Service
Level 2 Executive Suite, Royal Newcastle Centre
Lookout Rd
New Lambton NSW 2305</address>
      <phone>61 2 49223435</phone>
      <fax>61 2 49223574</fax>
      <email>Jeanene.Douglas@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>